Rchr
J-GLOBAL ID:200901092641070815   Update date: Dec. 05, 2024

Yamamoto Norio

ヤマモト ノリオ | Yamamoto Norio
Affiliation and department:
Research field  (1): Orthopedics
Research keywords  (2): 骨腫瘍 軟部腫瘍 四肢 肉腫 化学療法 患肢温存 ,  BONE TUMOR SOFT TISSUE TUMOR LIMB sarcoma Chemotherapy limb salvage
Research theme for competitive and other funds  (13):
  • 2021 - 2026 液体窒素を用いた腫瘍処理骨再建術における処理骨周囲膜組織の機能解明
  • 2022 - 2025 Investigation of microenvironment and novel therapeutic targets in bone and soft tissue tumors
  • 2022 - 2025 神経原性腫瘍モデルラットの新規構築と検証
  • 2020 - 2025 悪性軟部腫瘍個別化療法のための新規同所移植モデル確立とその機能解析
  • 2021 - 2024 骨軟部肉腫における腫瘍免疫状態の解明と新規免疫療法の開発
Show all
Papers (410):
  • Sei Morinaga, Qinghong Han, Kohei Mizuta, Byung Mo Kang, Michael Bouvet, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, et al. Selective Synergy of Recombinant Methioninase Plus Docetaxel Against Docetaxel-resistant and -sensitive Fibrosarcoma Cells Compared to Normal Fibroblasts. Anticancer research. 2024. 44. 12. 5207-5213
  • Sei Morinaga, Qinghong Han, Kohei Mizuta, Byung M Kang, Michael Bouvet, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, et al. Recombinant Methioninase Synergistically Reverses High-docetaxel Resistance Developed in Osteosarcoma Cells. Anticancer research. 2024. 44. 11. 4773-4778
  • Yohei Asano, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi, Satoshi Kato, Shinji Miwa, Miho Okuda, Isao Matsumoto, Seiji Yano, Satoru Demura. Serum Inflammatory Dynamics as Novel Biomarkers for Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer With Bone Metastases. Anticancer research. 2024. 44. 10. 4493-4503
  • 樋口 貴史, 山本 憲男, 林 克洋, 武内 章彦, 三輪 真嗣, 五十嵐 健太郎, Hoffman Robert M., 土屋 弘行, 出村 諭. PPARγ選択的アゴニストはP-glycoproteinを介して骨肉腫のドキソルビシン耐性を克服する. 日本整形外科学会雑誌. 2024. 98. 8. S1888-S1888
  • Sei Morinaga, Qinghong Han, Kohei Mizuta, Byung Mo Kang, Motokazu Sato, Michael Bouvet, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, et al. Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma. Anticancer research. 2024. 44. 9. 3777-3783
more...
MISC (652):
Education (6):
  • - 2000 Kanazawa University
  • - 2000 Kanazawa University Graduate School, Division of Medical Science
  • - 1999 Kanazawa University
  • - 1999 Kanazawa University Graduate School, Division of Medicine
  • - 1993 Kanazawa University
Show all
Work history (4):
  • 2001 - 2003 : カリフォルニア大学サンディエゴ校 研究員
  • 2001 - 2003 :
  • 2000 - -: 金沢大学 助手
  • 2000 - -: Kanazawa University
Awards (1):
  • 2000 - イギリス整形外科学会フェロー
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page